Key result
Valsartan and other ARBs face widespread recalls due to manufacturing contamination with probable human carcinogens.
Why the study?
Recent recalls of formulations containing different ARBs raised major safety concerns, prompting a review of the molecular-pharmaceutical basis of valsartan and other drug recalls.
Design
Literature review
Authors
Loading...
Prompts vigilance for nitrosamine exposure in sartan users; leaves open long-term cancer risk quantification in exposed cohorts.
Highlights the molecular basis of recent sartan recalls due to carcinogenic nitrosamine impurities, emphasizing the need for periodic quality assessment in drug manufacturing.
Ray et al. (2020) conducted a review in Hypertension and heart failure. Sartans (Valsartan) was evaluated. Valsartan and other sartan medications have been subject to widespread recalls due to contamination with probable human carcinogens, including NDMA, NDEA, and NMBA, during the manufacturing process.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: